Citizens Jmp Issues Pessimistic Forecast for KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective cut by stock analysts at Citizens Jmp from $29.00 to $28.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the specialty pharmaceutical company’s stock. Citizens Jmp’s price target points to a potential upside of 44.85% from the company’s current price.

A number of other brokerages have also weighed in on KALV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Needham & Company LLC increased their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. HC Wainwright boosted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.60.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $19.33 on Thursday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The stock has a 50 day simple moving average of $16.04 and a 200 day simple moving average of $14.46. KalVista Pharmaceuticals has a 52-week low of $9.23 and a 52-week high of $19.95. The firm has a market capitalization of $990.08 million, a PE ratio of -4.89 and a beta of -0.35.

Insider Activity

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the transaction, the insider owned 5,129,340 shares of the company’s stock, valued at $86,942,313. This represents a 3.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Brian Piekos sold 1,767 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $27,512.19. Following the transaction, the chief financial officer directly owned 13,762 shares of the company’s stock, valued at $214,274.34. This represents a 11.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 248,009 shares of company stock worth $4,213,467. 4.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KALV. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at $24,360,000. Vestal Point Capital LP lifted its position in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after buying an additional 1,140,000 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after buying an additional 1,055,940 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after buying an additional 905,053 shares during the last quarter. Finally, Elmind Capital LP bought a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $12,941,000.

More KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.